UBS Initiates Coverage of 10X Genomics, PacBio, Akoya Biosciences, NanoString Technologies
The investment bank gave 10X Genomics and PacBio a Neutral rating, and Akoya and NanoString a Buy rating.
The drug discovery and bioinformatics firm, which was recently chosen to be part of a Merck-supported accelerator program, believes that transomics is more integrated and comprehensive than multiomics.
Caris Life Sciences, ConcertAI Partner on Molecular Oncology R&D Platform
Caris and ConcertAI will combine their multiomic and multimodal databases and AI technology to create a unified platform for use in oncology and hematology.
Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D
Cold Spring Harbor spinout Envisagenics will apply its AI technology to multiomics data in pursuit of new therapies for acute myeloid leukemia and other hematopoietic cancers.
Researchers scanned cancer-related pathways in DNA repair disorders with high cancer prevalence as a means to search for new biomarkers and therapeutic targets.